Researchers are rapidly examining retatrutide, a novel medication created by Eli Lilly, as a potential advance in physique loss . Unlike many existing approaches, retatrutide is a dual -action agonist targeting both GLP-1 and GIP, substances that affect satiety and glucose control . Preliminary p… Read More